RT Journal Article SR Electronic T1 Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases JF European Respiratory Review JO EUROPEAN RESPIRATORY REVIEW FD European Respiratory Society SP 180078 DO 10.1183/16000617.0078-2018 VO 27 IS 150 A1 Colin Holtze A1 Kevin Flaherty A1 Michael Kreuter A1 Fabrizio Luppi A1 Teng Moua A1 Carlo Vancheri A1 Mary B. Scholand YR 2018 UL http://err.ersjournals.com/content/27/150/180078.abstract AB There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.Data for ILDs with a progressive fibrosing phenotype are lacking, but the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF http://ow.ly/Eoht30mS4Nx